Ascentage Pharma’s ASCO Data: 91.3% CCyR in CML, 80% DCR in Sarcoma
AAPG•Ascentage Pharma’s ASCO 2026 data showed olverembatinib delivered 91.3% CCyR and 60.9% MMR by cycle 24 in 42 CP-CML patients, and combination with blinatumomab yielded CR or MRD negativity in four of five Ph+ ALL/CML-LBP subjects. Alrizomadlin plus lisaftoclax achieved 30% ORR and 80% DCR with no dose-limiting toxicities.
1. ASCO Abstract Presentations
Ascentage Pharma had six abstracts selected for ASCO 2026, comprising three rapid oral and three poster presentations that highlight its lead candidates olverembatinib, lisaftoclax and alrizomadlin.
2. Olverembatinib Efficacy in Adult Leukemias
In a phase Ib study, olverembatinib plus blinatumomab achieved complete responses or MRD negativity in four of five Ph+ BCP-ALL/CML-LBP patients. A separate second-line CP-CML trial in 42 patients reported 91.3% CCyR and 60.9% MMR by cycle 24 with a favorable safety profile.
3. Alrizomadlin + Lisaftoclax in Pediatric Sarcomas
A multicenter pediatric trial in relapsed/metastatic neuroblastoma and soft-tissue sarcomas observed no dose-limiting toxicities and demonstrated a 30% objective response rate alongside an 80% disease control rate.
4. Ongoing Phase III POLARIS-2 Study
The global, registrational POLARIS-2 trial, cleared by FDA and EMA, is evaluating olverembatinib in chronic-phase CML with two independent cohorts, aiming to confirm efficacy and support potential registration.
